While complying with local directives, Cellecta is fully operational. Normal turnaround times have not been affected by COVID-19 more >

Menu
0

While complying with local directives, Cellecta is fully operational. Normal turnaround times have not been affected by COVID-19 more >

0

Your Cart is Empty

Press Releases

Main menu

CELLECTA, Inc. Launches the First Commercially Available Dual-sgRNA Libraries for CRISPRa and CRISPRi Genetic Screens
June 26, 2019 (PR Newswire)

Cellecta today announced the launch of the first commercially available dual sg-RNA libraries designed for CRISPR activation and CRISPR interference genetic screens. These new pooled libraries enhance activation or repression of genes producing more robust results from genetic screens.

CELLECTA, Inc. Launches five DriverMap™ Predesigned RNA-Seq Panels and Analysis Software
December 10, 2018 (PR Newswire)

Cellecta today announced the launch of five DriverMap™ Predesigned RNA-Seq Panels. Each panel measures expression levels of over 1200 expertly curated essential genes selected from publications, open access databases, and other resources.

CELLECTA, Inc. Introduces CloneTracker XP™ Expressed Lentiviral Barcode Libraries and CloneTracker XP™ Barcoded CRISPR Libraries
October 9, 2018 (PR Newswire)

Cellecta today introduced the CloneTracker XP™ Expressed Lentiviral Barcode Libraries and CloneTracker XP™ Barcoded CRISPR Libraries which enable a new approach for tracking clonal variations in large cell populations.

CELLECTA, Inc. Signs License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services
November 10, 2017 (PR Newswire) 

Cellecta, Inc. and ERS Genomics announced a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property for use in informing research tools and services.

CELLECTA, Inc. Introduces CRISPRa and CRISPRi Genome-Wide sgRNA Libraries and Mouse Genome-Wide CRISPR Knockout Library to Expand Functional Genomic Screening Portfolio
October 2, 2017 (PR Newswire)

Cellecta, Inc. introduced  CRISPRa (for activation) and CRISPRi (for inhibition) genome-wide, human and mouse pooled screening libraries to its extensive portfolio of CRISPR products and services. Cellecta also supplemented its current portfolio of CRISPR gene knockout libraries by adding a Mouse Genome-Wide CRISPR Knockout Library.

CELLECTA, Inc. Launches DriverMap™ Human Genome-Wide Gene Expression Profiling Kit for 19,000 Human Genes
March 29, 2017 (PR Newswire)

Cellecta, Inc. announced  the launch of the DriverMap™ Human Genome-Wide Gene Expression Profiling kit, a targeted RNA expression profiling assay designed to easily provide a molecular snapshot of all known 19,000 human protein-coding genes from complex samples starting from as little as 10 pg of total RNA. The DriverMap assay kit includes a complete set of gene-specific and PCR-NGS primer, buffers, spike-in ERCC and positive control RNAs as well as all other reagents required to profile 24 samples and prepare them for digital expression profiling using next-generation sequencing on an Illumina platform.

CELLECTA, INC. Announces Upcoming Presentations at the American Association for Cancer Research 2017 Annual Meeting
March 15, 2017 (PR Newswire)

Cellecta, Inc. announced that it will deliver three scientific presentations at the upcoming American Association for Cancer Research (AACR) 2017 Annual Meeting, which will take place April 1-5, 2017 in Washington, D.c. Cellecta researchers will present technology developments in genetic screens using CRISPR, as well as new data on applicaiton of the DriverMap targeted RNA expression profiling solution.

CELLECTA, INC. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform
January 26, 2017 (PR Newswire)

Cellecta, Inc. announced the receipt of Phase II SBIR grant funds from the National Institute of Health (NIH) to advance development of CRISPR/Cas9 library technology. These advances will improve the performance and increase the utility of genetic screens for disease studies. The improved screening platform will include genome-wide human and mouse CRISPR libraries and incorporate innovative features, such as multiple expression of sgRNAs that result in more effective irreversible gene disruption, enhanced gene activation (CRISPRa), or gene inhibition (CRISPRi). These technology improvements will be made available to the research community and are expected to lead to enhanced drug discovery in many therapeutic areas.

CELLECTA, INC. Releases Single-Module 80K Human Genome-Wide CRISPR Knockout Library
December 20, 2016 (PRNewswire)

Cellecta, Inc. announced the release of its new pooled single-module CRISPR Human Genome-Wide 80K Knockout Library. The reduced library size enables the study of gene disruptions across the entire human genome in a single screening experiment. This new 80K library incorporates the new design rules for sgRNA gene targeting as well as Cellecta's more effective HEAT sgRNA structure, which increases the knockout efficiency of the guide RNAs.

CELLECTA, INC. Launches DriverMap (TM) Human Genome-Wide Expression Profiling Service for 19,000 Human Genes
November 29, 2016 (PRNewswire)

Cellecta, Inc. announced the launch of DriverMap Human Genome-Wide Expression Profiling Service, a targeted RNA expression method that allows quantitative expression analysis of all known 19,000 protein-coding genes in the human genome from as little as 10 pg of total RNA. The multiplex RT-PCR-based-, followed by next-generation sequencing (NGS), method addresses the limitations in specificity, reproducibility and sensitivity of other genome-wide expression profiling approaches such as RNA-Seq and microarray platforms.

CELLECTA, INC. SBIR Grant Work Finds Way to Increase CRISPR Effectiveness for Genetic Screens
April 12, 2016 (PRNewswire)

Cellecta, Inc. developed an approach that improves CRISPR single-guide RNA (sgRNA) designs with the successful completion of its NIH Phase I SBIR grant "CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform." The results move forward Cellecta's goal of developing a library of validated CRISPR guide RNA sequences that can be used to improve the efficiency of CRISPR genome-wide genetic knockout screens. Dr. Donato Tedesco, senior scientist at Cellecta and the lead scientist on this study expressed his excitement about the findings by noting that, "The results of this work are actually very practically useful since they provide an approach to improve the effectiveness of any sgRNA regardless of the gene it targets. A few modifications of the constant region of the sgRNA produce a marked increase in the rate of CRISPR-mediated gene knockout and significantly increase the strength of the data signal in a genetic screen."

CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library
July 31, 2015 (PRNewswire)

Cellecta announced the release of its pooled CRISPR Guide RNA (sgRNA or gRNA) Knockout Library targeting nearly all human protein coding genes. This makes it the first company to produce a lentiviral based CRISPR library that targets nearly all of the almost 20,000 protein encoding genes in the human genome. The CRISPR Human Genome Knockout Library, as it is called, was designed as three modules each targeting approximately a third of the human genome with eight sgRNAs per gene, which is a higher number than most

other libraries use. In addition, the sgRNAs in Cellecta's library incorporate improved design features that increase their effectiveness and they have been filtered to ensure they are unique for each gene target to minimize false positive results.  Download PDF>

CELLECTA, INC. Receives NIH SBIR Grant to Develop Validated CRISPR Knockout Library of Guide RNA (sgRNA) Sequences
July 17, 2015 (PRNewswire)

Cellecta announces the receipt of Phase I SBIR grant funds from the National Institute of Health (NIH) to further its CRISPR-mediated genome-editing program. The goal of the "CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform" grant is to develop a validated set of reagents that can be used for specific targeted disruption of all human and mouse genes. This resource will provide a powerful tool for researchers to identify, in a single experiment, the genes that are important for cell growth, drug effectiveness, or other biological responses and has wide implications in the discovery of novel drug targets and identifying drug mechanisms.

CELLECTA, INC. Receives Second Phase Contract from the National Cancer Institute (NCI) to Identify Lethal Gene Combinations in Cancer Cell Models
October 23, 2012 (PRWeb)

Cellecta received a Phase II SBIR contract from the National Cancer Institute to identify combinations of DNA damage and repair genes that are essential for cancer cells. There is great interest in these lethal gene combinations for drug development since therapies targeting multiple genes simultaneously can be much more effective at minimizing acquired resistance to a treatment over time. However, identification of these pairs is problematic using standard serial assays. Cellecta’s pooled RNAi screening solves this problem.

CELLECTA, INC. Receives Phase II NIH SBIR Grant to Screen for Therapeutic Targets for Blood Cancers
September 22, 2011 (PRWeb)

Cellecta receives a two-year $1.85M Phase II NIH/NCI SBIR grant to identify novel drug targets which interact with small molecules specifically lethal to hematopoietic cells. It is anticipated that this study will provide a basis to develop therapeutic treatments for blood cancers.

Addgene Helps Distribute Cellecta’s DECIPHER shRNA Libraries to the Academic Community
May 17, 2011 (PRLog)

In association with the DECIPHER Project, the non-profit plasmid repository Addgene is now distributing a set of short hairpin RNA (shRNA) pooled libraries to the academic community. Altogether, the libraries cover over 15,000 human genes and nearly 10,000 mouse genes (http://www.addgene.org/decipher)

Cellecta, Inc. Releases the DECIPHER Project’s Third Module of the Human Lentiviral RNAi Library for Functional Screening
February 24, 2011 (PRWEB)

Cellecta, Inc. released the 3rd Module of the DECIPHER Project Pooled shRNA Library which targets an additional 5,000 human genes. This new Human Library Module adds additional cell surface, extracellular, DNA binding targets, and other genes to the well-annotated signal transduction and disease-associated genes primarily targeted with the first two modules of the human shRNA library.

Cellecta, Inc. Announces Launch of the Open Source DECIPHER Project to Provide Free Access to RNAi Genetic Screen Tools
October 28, 2010 (PRWEB)

Cellecta announces the DECIPHER Project–an open source platform for genome-wide RNAi screening and analysis that provides free-of-charge access to shRNA libraries and software for genome-wide functional screening for researchers from academic and non-profit institutions.

Cellecta, Inc. Receives Contract from the National Cancer Institute (NCI) to Identify Synthetically Lethal Breast Cancer Genes
September 30, 2010 (PRWeb)

Cellecta has received a $200K SBIR contract from the NCI to identify combinations of genes that, when silenced together, trigger death of cancer cells. These synthetic-lethal gene combinations can be difficult to identify with standard screening approaches, but Cellecta’s pooled lentiviral shRNA gene-suppressor library platform can be readily adapted for these types of anticancer drug target combinatorial screens.

Cellecta, Inc. Receives $1.8M Phase II NIH SBIR Grant to Screen for Potential Breast Cancer Drug Targets
September 16, 2010 (PRWeb)

Cellecta, in collaboration with The Scripps Research Institute, starts the next phase of its project to find new breast cancer drug targets by using its pooled lentiviral gene suppressor libraries to screen human isogenic mammary epithelial (HMEC) cells in genome-wide scale.

Cellecta to collaborate with Ariadne and Roswell Park Cancer Institute to Develop Knowledgebase of Pathways for Prostate Cancer
August 16, 2010 (GenomeWeb)

Ariadne, Cellecta, and the Roswell Park Cancer Institute today announced they will collaborate to develop a knowledgebase of prostate-specific pathway models. Under the agreement, Cellecta will use its DECIPHER™ functional genomics technology to screen for a panel of prostate cancer cell lines to identify genes that are essential for cancer cell viability. From that, Ariadne will use available ’omics data to identify the pathways involved and to “build mechanistic models in support of the genes identified from the siRNA targets in the screen,” the Rockville, Md., company said in a statement.

CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
September 16, 2009 (PRWeb)

Cellecta issued a press release announcing that the company has been awarded a subcontract to assist the scientists at Roswell Park Cancer Institute and Health Research, Inc. in developing a new technology for the discovery of cancer-related genes using HT insertional mutagenesis.